Aytu Biopharma AYTU
NASDAQ AYTU
$1.79 -0.04 (-2.19%)
At close: Nov 9, 2026 · 4:00 PM EST

Aytu Biopharma (AYTU) Cash from Restructuring (2017)

Updated

Analysis

Aytu Biopharma (AYTU) Cash from Restructuring (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Aytu Biopharma 22.17 Mn -93.50 Mn 10.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2017 1,500.00
API Access

Aytu Biopharma Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=AYTU&period=max&api_key=YOUR_API_KEY